Maxime Verhoeven

54 Chapter 3 SUPPLEMENTARY FILE Supplementary Table S1 gives an overview of baseline characteristics for all strategy arms per trial. Supplementary Table S1 Baseline characteristics for all treatment strategy arms per trial. U-Act-Early CAMERA-II TCZ+MTX n=106 TCZ n=103 MTX (ref) n= 108 MTX+Pred n= 117 MTX (ref) n= 119 Female, n (%) 65 (61) 78 (76) 69 (64) 70 (60) 72 (61) Age (yrs.), mean (SD) 53.1 (11.8) 55.0 (12.9) 52.2 (13.7) 54.4 (13.8) 53.0 (13.0) BMI (kg/m²), mean (SD) 26.5 (4.8) 25.9 (3.9) 26.2 (4.3) 25.7 (4.1) 25.9 (4.0) Alcohol use (≥1 unit/ week), n (%) 64 (60) 63 (61) 65 (60) 43 (41) 41 (39) Current smoker, n (%) 36 (34) 23 (22) 31 (29) 38 (32) 31 (28) Education level, n (%) Low Moderate High 45 (45) 38 (38) 17 (17) 30 (31) 36 (37) 31 (32) 48 (49) 37 (37) 14 (14) 35 (46) 26 (33) 16 (21) 41 (29) 27 (47) 22 (24) Disease duration (days), median (IQR) 24.5 (16.0 – 14.5) 25.5 (18.0 – 45.0) 27.0 (15.0 – 46.0) * * RF-positive status, n (%) 75 (71) 69 (67) 87 (81) 51 (44) 67 (68) DAS28, mean (SD) 5.1 (1.1) 5.3 (1.2) 5.1 (1.2) 5.8 (1.4) 5.6 (1.2) CRP (mg/L), median (IQR) 8.0 (3.1 – 18.0) 9.0 (3.0 – 24.0) 9.6 (3.0 – 23.0) 17.0 (0.0 – 44.0) 17.0 (8.0 – 41.5) ESR (mm per h), median (IQR) 23.5 (15.0 – 41.0) 27.0 (14.0 – 47.0) 25.0 (12.0 – 46.0) 31.0 (16.0 – 48.0) 30.0 (15.0 – 48.0) SJC28, median (IQR) 6.5 (3.0 – 10.0) 7.0 (4.0 – 13.0) 6.0 (3.0 – 10.0) 11.0 (6.0 – 15.0) 9.0 (6.0 – 15.0) TJC28, median (IQR) 6.0 (4.0 – 11.0) 7.0 (4.0 – 11.0) 7.0 (4.0 – 10.0) 10.0 (6.0 – 17.0) 9.0 (5.0 – 13.0) HAQ score, median (IQR) 1.1 (0.6 – 1.6) 1.1 (0.9 – 1.6) 1.0 (0.6 – 1.4) 1.0 (0.4 – 1.5) 1.3 (0.8 – 1.6) Any radiographic joint damage, n (%) 26 (25) 28 (27) 29 (27) 33 (28) 24 (20) Outcomes are based on non-imputed data of the 2 trials. Reported baseline characteristics of CAMERA- II slightly differ from those of the original publication as we presented non-imputed data compared to imputed data in that publication. 6,12 * not collected in CAMERA-II, but at least <1 year according to the inclusion criteria. TCZ+MTX= tocilizumab + methotrexate strategy arm; TCZ= tocilizumab + placebo strategy arm; MTX (ref)= methotrexate + placebo strategy reference arm; MTX+Pred= methotrexate + prednisone strategy arm; SD= standard deviation; BMI= body mass index; RF= rheumatoid factor; DAS28= disease activity score assessing 28 joints [range 0-9.4, higher is more activity]; CRP= C-reactive protein in milligram per litre; IQR= interquartile range; ESR= erythrocyte sedimentation rate in millimetre per hour; SJC28= 28 swollen joint count; TJC28= 28 tender joint count; HAQ= health assessment questionnaire [range 0-3, 3= worst function]; any radiographic joint damage= total Sharp van der Heijde score ≥1.